6 completed, 2 terminated, 1 withdrawn. 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 2, Withdrawn 1 |
Follow fevipiprant: new trials by email Literature Review of fevipiprant trials Research Report on fevipiprant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma. QAW039 - Asthma, Asthma, Bronchial | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2019-10-15 | 2020-05-14 | |
| A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia QAW039, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Novartis Pharmaceuticals | 9 | 2019-05-21 | 2021-10-08 |
| Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma Fevipiprant - Asthma | Phase 2 | Terminated | Novartis Pharmaceuticals | 11 | 2019-05-01 | 2026-01-13 |
| Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis. QAW039, Placebo - Atopic Dermatitis | Phase 2 | Completed | Novartis Pharmaceuticals | 103 | 2013-06-01 | 2015-12-15 |
| A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients QAW039, Placebo QAW039, Fluticasone 250 mcg - Asthma | Phase 2 | Completed | Novartis Pharmaceuticals | 345 | 2013-05-01 | 2017-03-20 |
| A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber QAW039, Montelukast, Placebo - Allergic Rhinitis | Phase 2 | Completed | Novartis Pharmaceuticals | 188 | 2012-10-01 | 2016-11-18 |
| Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent Asthma QAW039, Placebo - Asthma | Phase 2 | Completed | Novartis Pharmaceuticals | 61 | 2012-02-01 | 2013-10-09 |
| Dose Finding Study for QAW039 in Asthma QAW039, Montelukast, Placebo - Asthma | Phase 2 | Completed | Novartis Pharmaceuticals | 1043 | 2011-08-01 | 2020-12-19 |
| Efficacy, Safety, and Pharmacokinetics of QAW039 QAW039 capsules once daily for 28 days, Placebo to QAW039 capsules once daily for 28 days, Fluticasone propionate inhaler twice daily for 28 days - Persistent Asthma | Phase 2 | Completed | Novartis Pharmaceuticals | 170 | 2010-11-01 | 2020-12-19 |
Asthma (6) · Eosinophilia (2) · Dermatitis, Atopic (1) · Pulmonary Disease, Chronic Obstructive (1) · Rhinitis, Allergic (1) · Skin Diseases (1)
Germany (5) · Romania (4) · United States (4) · Belgium (3) · South Africa (3) · United Kingdom (3) · Austria (2) · Bulgaria (2) · Colombia (2) · India (2) · Netherlands (2) · Poland (2) · South Korea (2) · Argentina (1) · Australia (1)
Richard Kay (1)
PMID 27354118, PMID 27503237, PMID 28838980
2018 (1)